# Orthofix Medical Inc.: financial statements, quarterly

OFIX · Nasdaq · CIK 884624 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 23

Pages: [Overview](/companies/ofix.md) · [Financials](/companies/ofix/financials.md) · [Filings](/companies/ofix/filings.md) · [Insiders](/companies/ofix/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ofix/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [184](/filings/0000950170-24-122782.md) | [200 d](/filings/0001193125-26-065189.md) | [189](/filings/0000950170-25-063956.md) | [199](/filings/0000950170-25-102384.md) | [197](/filings/0001193125-25-263670.md) | [216 d](/filings/0001193125-26-065189.md) | [194](/filings/0001193125-26-205003.md) | [203](/filings/0001193125-26-333822.md) | [206](/filings/0001193125-25-263670.md) | [220 d](/filings/0001193125-26-065189.md) | [197](/filings/0001193125-26-205003.md) | [211](/filings/0001193125-26-333822.md) |
| Cost of revenue | $m | [64.2](/filings/0000950170-24-122782.md) | [63.8 d](/filings/0001193125-26-065189.md) | [61.4](/filings/0000950170-25-063956.md) | [63.9](/filings/0000950170-25-102384.md) | [61.6](/filings/0001193125-25-263670.md) | [66.8 d](/filings/0001193125-26-065189.md) | [72.0](/filings/0001193125-26-205003.md) | [63.6](/filings/0001193125-26-333822.md) | [57.1](/filings/0001193125-25-263670.md) | [63.6 d](/filings/0001193125-26-065189.md) | [57.2](/filings/0001193125-26-205003.md) | [61.2](/filings/0001193125-26-333822.md) |
| Gross profit | $m | [120](/filings/0000950170-24-122782.md) | [137 d](/filings/0001193125-26-065189.md) | [127](/filings/0000950170-25-063956.md) | [135](/filings/0000950170-25-102384.md) | [135](/filings/0001193125-25-263670.md) | [149 d](/filings/0001193125-26-065189.md) | [122](/filings/0001193125-26-205003.md) | [140](/filings/0001193125-26-333822.md) | [149](/filings/0001193125-25-263670.md) | [156 d](/filings/0001193125-26-065189.md) | [140](/filings/0001193125-26-205003.md) | [150](/filings/0001193125-26-333822.md) |
| Research and development | $m | [18.6](/filings/0000950170-24-122782.md) | [18.9 d](/filings/0001193125-26-065189.md) | [19.5](/filings/0000950170-25-063956.md) | [18.0](/filings/0000950170-25-102384.md) | [17.3](/filings/0001193125-25-263670.md) | [18.8 d](/filings/0001193125-26-065189.md) | [19.8](/filings/0001193125-26-205003.md) | [15.9](/filings/0001193125-26-333822.md) | [14.8](/filings/0001193125-25-263670.md) | [15.4 d](/filings/0001193125-26-065189.md) | [15.3](/filings/0001193125-26-205003.md) | [15.9](/filings/0001193125-26-333822.md) |
| Selling, general and administrative | $m | not reported | not reported | [132](/filings/0000950170-25-063956.md) | [134](/filings/0000950170-25-102384.md) | [130](/filings/0001193125-25-263670.md) | [136 d](/filings/0001193125-26-065189.md) | [133](/filings/0001193125-26-205003.md) | [136](/filings/0001193125-26-333822.md) | [148](/filings/0001193125-25-263670.md) | [137 d](/filings/0001193125-26-065189.md) | [135](/filings/0001193125-26-205003.md) | [138](/filings/0001193125-26-333822.md) |
| Operating income | $m | [(24.4)](/filings/0000950170-24-122782.md) | [(18.3) d](/filings/0001193125-26-065189.md) | [(29.3)](/filings/0000950170-25-063956.md) | [(24.9)](/filings/0000950170-25-102384.md) | [(18.9)](/filings/0001193125-25-263670.md) | [(11.5) d](/filings/0001193125-26-065189.md) | [(48.9)](/filings/0001193125-26-205003.md) | [(16.0)](/filings/0001193125-26-333822.md) | [(17.0)](/filings/0001193125-25-263670.md) | [0.5 d](/filings/0001193125-26-065189.md) | [(14.4)](/filings/0001193125-26-205003.md) | [(8.1)](/filings/0001193125-26-333822.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.5](/filings/0000950170-24-122782.md) | [0.1 d](/filings/0001193125-26-065189.md) | [0.9](/filings/0000950170-25-063956.md) | [1.1](/filings/0000950170-25-102384.md) | [0.8](/filings/0001193125-25-263670.md) | [(0.6) d](/filings/0001193125-26-065189.md) | [1.0](/filings/0001193125-26-205003.md) | [(0.1)](/filings/0001193125-26-333822.md) | [0.5](/filings/0001193125-25-263670.md) | [0.0 d](/filings/0001193125-26-065189.md) | [0.1](/filings/0001193125-26-205003.md) | [0.8](/filings/0001193125-26-333822.md) |
| Net income | $m | [(28.9)](/filings/0000950170-24-122782.md) | [(22.2) d](/filings/0001193125-26-065189.md) | [(36.0)](/filings/0001193125-25-263670.md) | [(33.4)](/filings/0001193125-25-263670.md) | [(27.4)](/filings/0001193125-25-263670.md) | [(29.1) d](/filings/0001193125-26-065189.md) | [(53.1)](/filings/0001193125-26-333822.md) | [(14.1)](/filings/0001193125-26-333822.md) | [(22.8)](/filings/0001193125-25-263670.md) | [(2.2) d](/filings/0001193125-26-065189.md) | [(20.9)](/filings/0001193125-26-333822.md) | [(15.8)](/filings/0001193125-26-333822.md) |
| Diluted EPS | $ per share | [(0.77)](/filings/0000950170-24-122782.md) | not reported | [(0.95)](/filings/0000950170-25-063956.md) | [(0.88)](/filings/0000950170-25-102384.md) | [(0.71)](/filings/0001193125-25-263670.md) | not reported | [(1.35)](/filings/0001193125-26-205003.md) | [(0.36)](/filings/0001193125-26-333822.md) | [(0.57)](/filings/0001193125-25-263670.md) | not reported | [(0.52)](/filings/0001193125-26-205003.md) | [(0.39)](/filings/0001193125-26-333822.md) |
| Basic EPS | $ per share | [(0.77)](/filings/0000950170-24-122782.md) | not reported | [(0.95)](/filings/0000950170-25-063956.md) | [(0.88)](/filings/0000950170-25-102384.md) | [(0.71)](/filings/0001193125-25-263670.md) | not reported | [(1.35)](/filings/0001193125-26-205003.md) | [(0.36)](/filings/0001193125-26-333822.md) | [(0.57)](/filings/0001193125-25-263670.md) | not reported | [(0.52)](/filings/0001193125-26-205003.md) | [(0.39)](/filings/0001193125-26-333822.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.7](/filings/0000950170-24-122782.md) | [33.1](/filings/0001193125-26-065189.md) | [27.0](/filings/0000950170-25-063956.md) | [26.4](/filings/0000950170-25-102384.md) | [30.1](/filings/0001193125-25-263670.md) | [83.2](/filings/0001193125-26-065189.md) | [58.0](/filings/0001193125-26-205003.md) | [65.6](/filings/0001193125-26-333822.md) | [62.9](/filings/0001193125-25-263670.md) | [82.0](/filings/0001193125-26-333822.md) | [120](/filings/0001193125-26-205003.md) | [104](/filings/0001193125-26-333822.md) |
| Current assets | $m | [394](/filings/0000950170-23-061148.md) | [420](/filings/0000950170-25-026066.md) | [399](/filings/0000950170-24-053966.md) | [386](/filings/0000950170-24-091200.md) | [386](/filings/0000950170-24-122782.md) | [433](/filings/0001193125-26-065189.md) | [390](/filings/0000950170-25-063956.md) | [396](/filings/0000950170-25-102384.md) | [394](/filings/0001193125-25-263670.md) | [417](/filings/0001193125-26-333822.md) | [462](/filings/0001193125-26-205003.md) | [446](/filings/0001193125-26-333822.md) |
| Total assets | $m | [906](/filings/0000950170-23-061148.md) | [925](/filings/0000950170-25-026066.md) | [906](/filings/0000950170-24-053966.md) | [882](/filings/0000950170-24-091200.md) | [868](/filings/0000950170-24-122782.md) | [893](/filings/0001193125-26-065189.md) | [823](/filings/0000950170-25-063956.md) | [837](/filings/0000950170-25-102384.md) | [833](/filings/0001193125-25-263670.md) | [851](/filings/0001193125-26-333822.md) | [887](/filings/0001193125-26-205003.md) | [873](/filings/0001193125-26-333822.md) |
| Current liabilities | $m | [153](/filings/0000950170-23-061148.md) | [165](/filings/0000950170-25-026066.md) | [151](/filings/0000950170-24-053966.md) | [156](/filings/0000950170-24-091200.md) | [162](/filings/0000950170-24-122782.md) | [169](/filings/0001193125-26-065189.md) | [144](/filings/0000950170-25-063956.md) | [148](/filings/0000950170-25-102384.md) | [160](/filings/0001193125-25-263670.md) | [170](/filings/0001193125-26-333822.md) | [161](/filings/0001193125-26-205003.md) | [157](/filings/0001193125-26-333822.md) |
| Total liabilities | $m | [290](/filings/0000950170-23-061148.md) | [327](/filings/0000950170-25-026066.md) | [336](/filings/0000950170-24-053966.md) | [336](/filings/0000950170-24-091200.md) | [342](/filings/0000950170-24-122782.md) | [390](/filings/0001193125-26-065189.md) | [365](/filings/0000950170-25-063956.md) | [379](/filings/0000950170-25-102384.md) | [390](/filings/0001193125-25-263670.md) | [401](/filings/0001193125-26-333822.md) | [451](/filings/0001193125-26-205003.md) | [444](/filings/0001193125-26-333822.md) |
| Long-term debt | $m | [70.0](/filings/0000950170-23-061148.md) | [93.1](/filings/0000950170-25-026066.md) | [115](/filings/0000950170-24-053966.md) | [113](/filings/0000950170-24-091200.md) | [112](/filings/0000950170-24-122782.md) | [157](/filings/0001193125-26-065189.md) | [157](/filings/0000950170-25-063956.md) | [157](/filings/0000950170-25-102384.md) | [157](/filings/0001193125-25-263670.md) | [157](/filings/0001193125-26-333822.md) | [221](/filings/0001193125-26-205003.md) | [222](/filings/0001193125-26-333822.md) |
| Current portion of debt | $m | not reported | [1.3](/filings/0000950170-25-026066.md) | [3.1](/filings/0000950170-24-053966.md) | [4.7](/filings/0000950170-24-091200.md) | [6.3](/filings/0000950170-24-122782.md) | [0.0](/filings/0001193125-26-065189.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-065189.md) | not reported | not reported |
| Shareholders' equity | $m | [615](/filings/0000950170-24-122782.md) | [599](/filings/0001193125-26-065189.md) | [570](/filings/0001193125-25-263670.md) | [546](/filings/0001193125-25-263670.md) | [526](/filings/0001193125-25-263670.md) | [503](/filings/0001193125-26-333822.md) | [458](/filings/0001193125-26-333822.md) | [458](/filings/0001193125-26-333822.md) | [442](/filings/0001193125-25-263670.md) | [450](/filings/0001193125-26-333822.md) | [435](/filings/0001193125-26-333822.md) | [429](/filings/0001193125-26-333822.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [0.5 d](/filings/0000950170-24-122782.md) | [(6.7) d](/filings/0001193125-26-065189.md) | [(18.6)](/filings/0000950170-25-063956.md) | [9.0 d](/filings/0000950170-25-102384.md) | [11.7 d](/filings/0001193125-25-263670.md) | [23.7 d](/filings/0001193125-26-065189.md) | [(18.4)](/filings/0001193125-26-205003.md) | [11.6 d](/filings/0001193125-26-333822.md) | [12.4 d](/filings/0001193125-25-263670.md) | [27.7 d](/filings/0001193125-26-065189.md) | [(17.6)](/filings/0001193125-26-205003.md) | [(6.2) d](/filings/0001193125-26-333822.md) |
| Capital expenditure | $m | [21.9 d](/filings/0000950170-24-122782.md) | [14.6 d](/filings/0000950170-24-025877.md) | [10.5](/filings/0000950170-24-053966.md) | [9.3 d](/filings/0000950170-24-091200.md) | [5.3 d](/filings/0000950170-24-122782.md) | [9.7 d](/filings/0001193125-26-065189.md) | [6.7](/filings/0001193125-26-205003.md) | [7.1 d](/filings/0001193125-26-333822.md) | [9.9 d](/filings/0001193125-25-263670.md) | [10.9 d](/filings/0001193125-26-065189.md) | [10.7](/filings/0001193125-26-205003.md) | [12.6 d](/filings/0001193125-26-333822.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-061148.md) | [0.0](/filings/0000950170-24-053966.md) | [0.0](/filings/0000950170-24-091200.md) | [37.2](/filings/0000950170-24-122782.md) | [37.7](/filings/0000950170-25-063956.md) | [38.0](/filings/0000950170-25-102384.md) | [38.5](/filings/0001193125-25-263670.md) | [39.2](/filings/0001193125-26-205003.md) | [39.5](/filings/0001193125-26-333822.md) | [39.8](/filings/0001193125-25-263670.md) | [40.5](/filings/0001193125-26-205003.md) | [40.9](/filings/0001193125-26-333822.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 40,732,608 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333822.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.